期刊文献+

Synthesis and Crystal Structure of (4S)-5-(2-Methoxy-2-oxoethylamino)-5-oxo- 4-(3,4,5-trimethoxybenzamido) Pentanoic Acid

Synthesis and Crystal Structure of (4S)-5-(2-Methoxy-2-oxoethylamino)-5-oxo- 4-(3,4,5-trimethoxybenzamido) Pentanoic Acid
下载PDF
导出
摘要 The crystal structure of (4S)-5-(2-methoxy-2-oxoethylamino)-5-oxo-4-(3,4,5- trimethoxybenzamido) pentanoic acid 5 (C18H24N2O9, Mr = 412.39) has been determined by single- crystal X-ray diffraction analysis. The crystal belongs to monoclinic, space group P21/c with a = 27.665(9), b = 5.1444(16), c = 13.907(4) ?, β = 98.401(5)o, V = 1958.0(11) ?3, Z = 4, Dc = 1.399 g/cm3, μ = 0.113 mm-1, F(000) = 872, R = 0.0606 and wR = 0.1405 (I > 2σ(I)). The results con- firmed that 5 could be assigned to the tautomeric form. The intermolecular hydrogen bonds between O(5)–H(5)…O(7), N(2)–H(2)…O(6) and N(1)–H(1)…O(4) have been observed. The crystal structure of (4S)-5-(2-methoxy-2-oxoethylamino)-5-oxo-4-(3,4,5- trimethoxybenzamido) pentanoic acid 5 (C18H24N2O9, Mr = 412.39) has been determined by single- crystal X-ray diffraction analysis. The crystal belongs to monoclinic, space group P21/c with a = 27.665(9), b = 5.1444(16), c = 13.907(4) ?, β = 98.401(5)o, V = 1958.0(11) ?3, Z = 4, Dc = 1.399 g/cm3, μ = 0.113 mm-1, F(000) = 872, R = 0.0606 and wR = 0.1405 (I > 2σ(I)). The results con- firmed that 5 could be assigned to the tautomeric form. The intermolecular hydrogen bonds between O(5)–H(5)…O(7), N(2)–H(2)…O(6) and N(1)–H(1)…O(4) have been observed.
机构地区 CollegeofPharmacy
出处 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 北大核心 2005年第6期706-710,共5页 结构化学(英文)
基金 The project was supported by the National Natural Science Foundation of China (No. 20272033) and the Doctoral Foundation of Ministry of Education of China (No. 20020422024)
关键词 synthesis APN pentanoic acid crystal structure synthesis, APN, pentanoic acid, crystal structure
  • 相关文献

参考文献12

  • 1Stange, T.; Kettmann, U.; Holzhansen, H. J. Acta Histochem. 1996, 98, 323-331.
  • 2Yoneda, J.; Saiki, I.; Fujii, H.; Abe, F.; Kojima, Y.; Azuma, I. Clin Exp Metastasis. 1992, 10, 49-59.
  • 3Bedir, A.; Ozener, I. C.; Emerk, K. Nephron. 1996, 74, 110-113.
  • 4Shimizu, T.; Tani, K.; Hase,K.; Ogawa, H.; Huang, L. P.; Shinomiya, F.; Sone, S. Arthritis & Rheumatism. 2002, 46, 2330-2338.
  • 5Sato, Y. Biol. Pharm. Bull. 2004, 27,772-776.
  • 6Sloane, P. D.; Zimmerman, S.; Suchindran, C.; Reed, P.; Wang, L.; Boustani, M.; Sudha, S. Annu. Rev. Public Health 2002, 23, 213-231.
  • 7Song, L.; Xie, Y. L.; Xie, Y. Y. J. Chin. Pharm. Sci. 2000, 9, 77-80.
  • 8Khalid, M. Drug Exptl. Clin. Res. 1987, 13, 57-50.
  • 9Sheldrick, G.M. SHELXS-97, Program for X-ray Crystal Structure Solution, Gottingen University, Germany 1997.
  • 10Sheldrick, G. M. SHELXS-97, Program for X-ray Crystal Structure Refinement, Gottingen University, Germany 1997.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部